相关实验视频

Updated: Jan 14, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

对于复发性/耐火性EBV+DLBCL型DLBCL型的移植后淋巴增殖障碍,使用epcoritamab

Li Yuan Chan¹, Simon O'Connor¹, Dima El-Sharkawi¹

¹Department of Haemato-Oncology The Royal Marsden NHS Foundation Trust Sutton UK.

|October 27, 2025

概括

移植后复发性/耐药性移植后淋巴增殖障碍 (PTLD) 在移植后的结果很差. 一个案例研究表明,Epcoritamab是一种CD3xCD20双特异性抗体,提供了耐受性良好,有效的治疗,具有长期反应.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

在实体器官移植 (SOT) 或血造干细胞移植 (HSCT) 之后,复发性/耐药性移植后淋巴增殖障碍 (R/R PTLD) 是一个严重的临床挑战,治疗选择有限.
目前对R/R PTLD的治疗模式缺乏标准的护理,受影响的患者经常被排除在临床试验之外,突出了未满足的医疗需求.
最近扩散性大b细胞淋巴瘤 (DLBCL) 治疗的进展,包括CD19 CAR-T细胞疗法和CD3xCD20双特异性抗体,为PTLD提供了潜在的治疗途径.

研究的目的:

报告使用CD3xCD20双特异抗体进行R/R PTLD治疗的成功病例.
评估epcoritamab在R/R PTLD患者的耐受性和长期疗效.

主要方法:

一个单一中心病例报告,详细介绍了R/R PTLD患者的治疗.
用Epcoritamab作为治疗干预措施,作为一种CD3xCD20双特异抗体.
监测患者的反应,耐受性和长期结果.

主要成果:

患有R/R PTLD的患者通过使用Epcoritamab.b取得了成功的治疗结果.
治疗表现出良好的耐受性,没有报告任何重大不良事件.
观察到长期反应,表明持续的疾病控制.

结论:

CD3xCD20双特异抗体疗法,以Epcoritamab为例,显示出作为R/R PTLD有效治疗的承诺.
对于R/R PTLD患者来说,epcoritamab提供了耐受性良好的治疗选择,解决了关键的未满足需求.
需要进一步的研究和临床试验,以确定双特异性抗体在PTLD管理中的作用.

关键词:

这是EBV的EBV.两种特异性的抗体.扩散的大B细胞淋巴瘤移植后的淋巴增殖性疾病

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.